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Background: The	 cytomegalovirus	 (CMV)	 donor-	positive/recipient-	positive	 (D+/R+)	
population	is	the	largest	proportion	of	renal	transplant	recipients	(RTR).	Guidelines	for	
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1  | INTRODUCTION
Cytomegalovirus	(CMV)	continues	to	pose	a	significant	challenge	fol-
lowing	 renal	 transplantation	 owing	 to	 its	 high	 degree	 of	 associated	
morbidity.1,2	 The	 direct	 effects	 of	 CMV	 disease,	 such	 as	 viral	 syn-
drome,	tissue	invasion,	myelosuppression,	and	graft	dysfunction,	rep-
resent	significant	illness,	yet	it	is	the	indirect	effects	of	CMV	disease	









































VGCV	 is	 a	 prodrug	 for	GCV	and	exhibits	 superior	 bioavailability	
compared	to	oral	GCV.12	The	FDA-approved	dose	of	VGCV	for	pre-
vention	of	CMV	 in	high-	risk	RTR	 is	900	mg/day.	Despite	 its	 lack	of	
specific	FDA	approval	for	use	in	intermediate-	risk	patients,	most	cen-
ters	 utilize	 this	 agent	 in	 these	 patient	 populations	 and	 do	 so	 using	
the	approved,	guideline	recommended,	high-	dose	regimen.	However,	
some	 transplant	 centers	 utilize	 low-	dose	 (450	mg/day)	 prophylaxis	
based	 on	 pharmacokinetic	 (PK)	 data	 and	 experience.15,16	 Several	
groups	 have	 reported	 acceptable	 efficacy	 and	 tolerability	with	 low-	







Methods: A	multicenter,	 retrospective	 analysis	 evaluated	 478	 adult	 RTR	 between	
January	 2008	 and	 October	 2011.	 Study	 participants	 received	 VGCV	 450	mg/day	
(Group	1;	n=398)	or	900	mg/day	(Group	2;	n=89)×3	months	for	CMV	prophylaxis.	All	
VGCV	 was	 adjusted	 for	 renal	 function.	 All	 groups	 included	 in	 this	 study	 received	
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lation	 during	 the	 first	 12	months	 following	 transplantation.	 Adult	
RTR	who	were	transplanted	between	January	1,	2008	and	October	
31,	 2011	were	 evaluated.	 All	 patients’	 CMV	 prophylactic	 regimens	
were	 determined	 and	 implemented	 by	 individual	 transplant	 centers	
and	were	based	on	clinical	experience	and	center-	specific	protocols.	
Centers	 participating	 in	 this	 study	 employed	 standardized	 3-	month	
anti-	CMV	 regimens	 for	 all	 intermediate-	risk	 recipients	 during	 the	
evaluation	period.	Group	 I	 (n=398)	patients	were	 from	7	 transplant	
centers	and	received	450	mg/day	of	VGCV	and	patients	 in	Group	II	
(n=89)	 consisted	 of	 patients	 from	3	 transplant	 centers	 that	 utilized	















an	 organ	 from	 a	 CMV-seropositive	 donor.	 Patients	must	 have	 re-
ceived	induction	therapy	using	either	an	interleukin-	2	receptor	an-
tagonist	or	 rabbit	 anti-	thymocyte	globulin	 (rATG)	 to	ensure	 similar	
induction	regimens	for	all	centers.	 Initial	maintenance	therapy	was	




uation	 period	 remained	 in	 the	 study,	 despite	 data	 demonstrating	
that	 mTOR	 inhibitor-	based	 immunosuppression	 can	 reduce	 CMV-	
related	 complications.25	 Reasons	 for	 exclusion	 from	 this	 analysis	
included	patients	with	pre-	existing	 infection	from	human	 immuno-
deficiency	 virus,	 hepatitis	 B,	 hepatitis	 C,	 recipients	 of	multi-	organ	
transplantation	 (e.g.,	 kidney/pancreas,	 etc.),	 patients	 receiving	 no	
induction	 therapy	 or	 receiving	 induction	 therapy	 or	 initial	mainte-
nance	immunosuppression	using	any	agent	not	listed	in	the	inclusion	
criteria	 (e.g.,	OKT3,	 alemtuzumab,	 sirolimus,	 everolimus,	or	 azathi-


















with	 CMV	 disease	 were	 treated	 using	 institution-	specific	 practice	
guidelines.	CMV	viral	syndrome	was	defined	as	CMV	viremia	 identi-
fied	by	quantitative	polymerase	chain	reaction	or	pp65	antigenemia	








oped	CMV	disease	within	 12	months	 of	 transplantation.	 Secondary	
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TABLE  2 Patient	demographic	and	transplant	characteristic	data
Characteristic Group I (n=398) VGCV 450 mg/day Group II (n=89) VGCV 900 mg/day P- value
Age	(yrs) 49.9±13.2 51.6±13.5 .302
Weight	(kg)1 77.7±18.6 78.5±17.1 .456
Male	gender 230	(57.8%) 46	(51.7%) .344













Initial	transplant 352	(88.4%) 83	(93.3%) .253
rATG	induction 280	(70.4%) 37	(41.6%) <.001
ESW 30	(7.5%) 9	(10.1%) .393
mTOR	inhibitor	conversion 8	(2.0%) 1	(1.1%) 1.000
BPAR 41	(10.3%) 10	(11.2%) .848
Antibody-	mediated	rejection 8	(2.0%) 1	(1.1%) 1.000
Mean	TAC	conc.	(mg/dL)
Month	1 9.3±3.5	(n=396) 10.2±4.3	(n=86) .192
Month	2 9.1±3.5	(n=396) 10.3±3.8	(n=71) .002
Month	3 8.5±3.4	(n=389) 8.6±3.5	(n=65) .629
Month	6 7.5±3.1	(n=354) 8.7±4.1	(n=37) .052
Month	9 7.1±4.3	(n=349) 7.2±2.6	(n=35) .673
Month	12 6.9±3.0	(n=348) 8.6±2.6	(n=34) <.001
Mean	MPA	dose	(mg/day)2
Month	1 1856.7±3	70.4	(n=396) 1812.5±350.0	(n=88) .089
Month	2 1793.8±418.4	(n=394) 1726.2±428.0	(n=84) .089
Month	3 1725.9±450.5	(n=384) 1700.0±465.0	(n=75) .571
Month	6 1585.7±518.7	(n=356) 1634.3±519.2	(n=67) .378
Month	9 1544.9±516.3	(n=340) 1704.9±503.1	(n=61) .024

















908  |     HELDENBRAND Et AL.
2.4 | Statistical methods






























centers	 in	 the	United	 States.	 Baseline	 demographics	 and	 transplant	
characteristics	 were	 reported	 in	 Table	2.	 The	 low-	dose	 group	 con-
tained	 significantly	 more	 living-donor	 transplants	 (38.2%	 vs	 18.0%;	
P<.001)	 and	 more	 patients	 of	 self-	reported	 non-	white	 race	 (60.1%	
vs	 49.4%;	 P=.028).	 In	 terms	 of	 immunosuppression,	 induction	with	
rATG	use	was	more	common	in	the	low-	dose	group	(70.4%	vs	41.6%;	
P<.001).	The	 types	of	maintenance	 immunosuppressants	 used	were	
similar	between	the	2	groups,	including	early	steroid	withdrawal	and	










CMV	 disease	 occurrence	 was	 similar	 between	 the	 2	 groups	 (3.5%	
vs	3.4%;	P=1.000;	Table	3).	There	was	1	case	of	breakthrough	CMV	
disease	 in	 the	 high-	dose	 group	 and	no	GCV-	resistant	CMV	disease	
TABLE  3 Primary	and	secondary	efficacy	endpoints	at	12	months
Characteristic Group I (n=398) Group II (n=89) P- value
Primary	endpoint




CMV	diagnosis	(days) 143.4±42.4	(n=14) 157.3±107.4	(n=3) .499
Breakthrough	CMV 0 1
Resistant	CMV 0 0
Allograft	loss 17	(5.0%) 6	(6.7%) .403
Patient	death 7	(1.8%) 3	(3.4) .400
Opportunistic	infections 82	(20.6%) 25	(28.1%) .156
BKV	infection 58	(14.6%) 12	(13.5%) .869
Thrush 7	(1.8%) 5	(5.6%) .049
Herpes	infection 9	(2.3%) 2	(2.2%) 1.000
Systemic	fungal	infection 2	(0.5%) 3	(3.4%) .045
Other	opportunistic	infections 33	(8.3%) 16	(18.0%) .010
NODAT 29	(7.3%) 6	(6.7%) 1.000
CMV,	cytomegalovirus;	BKV,	BK	polyomavirus;	NODAT,	new-	onset	diabetes	after	transplant.





(donor	 type,	 rATG	 induction,	 and	premature	VGCV	discontinuation),	
















Characteristic Group I (n=398) Group II (n=89) P- value
VGCV	duration	(months)1 3.2±0.8 3.5±1.3 .002
Leukopenia	(white	blood	cell	<3	K/μL)
Month	1 6	(1.5%)	(n=398) 1	(1.1%)	(n=88) 1.000
Month	2 22	(5.5%)	(n=397) 3	(4.1%)	(n=74) .781
Month	3 57	(14.4%)	(n=395) 15	(22.7%)	(n=66) .099
Month	6 19	(5.2%)	(n=367) 2	(4.7%)	(n=43) 1.000
Month	9 11	(3.0%)	(n=362) 5	(12.2%)	(n=41) .016
Month	12 19	(5.2%)	(n=369) 0	(0%)	(n=41) .239
Thrombocytopenia	(platelets	<150	K/μL)
Month	1 51	(12.8%)	(n=398) 12	(13.6%)	(n=88) .861
Month	2 38	(9.6%)	(n=397) 9	(12.2%)	(n=74) .526
Month	3 35	(8.9%)	(n=395) 11	(16.7%)	(n=66) .072
Month	6 40	(10.9%)	(n=367) 6	(14.0%)	(n=43) .607
Month	9 38	(10.5%)	(n=362) 4	(9.8%)	(n=41) 1.000
Month	12 47	(12.8%)	(n=368) 5	(12.2%)	(n=41) 1.000
Platelets	(K/μL)
Month	1 247.8±100.4	(n=398) 246.6±97.2	(n=88) .839
Month	2 231.6±72.9	(n=397) 230.4±65.1	(n=74) .888
Month	3 230.8±75.5	(n=395) 225.6±82.4	(n=66) .417
Month	6 217.6±63.2	(n=367) 208.9±61.0	(n=43) .280
Month	9 216.7±64.4	(n=362) 219.3±62.4	(n=41) .783
Month	12 214.2±64.9	(n=368) 208.3±66.4	(n=41) .477











Month	12 1.4±0.8	(n=369) 1.6±0.7	(n=41) .005
eGFR	(mL/min/1.73	m2)
Month	12 52.9±20.0	(n=369) 45.9±19.8	(n=41) .011
CrCl	(mL/min)
Month	12 52.8±19.4	(n=368) 48.2±17.1	(n=41) .146
1One	patient	had	missing	actual	VGCV	duration.
VGCV,	 valganciclovir;	 G-	CSF,	 granulocyte	 colony-	stimulating	 factor;	 eGFR,	 estimated	 glomerular	 filtration	 rate	 (via	MDRD	 formula);	 CrCl,	 creatinine	
clearance.
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3.2.2 | Acute rejection and graft function
Overall,	 there	 were	 similar	 rates	 of	 biopsy-	proven	 acute	 rejec-
tion	 (BPAR)	 in	 the	 low-	dose	 group	 vs	 the	 high-	dose	 group	 (10.3%	
vs	11.2%;	P=.848)	 (Table	2).	Only	1	patient	 in	each	group	had	both	
BPAR	and	CMV	disease.	For	the	patients	in	the	low-	dose	group,	CMV	
diagnosis	 preceded	 the	 rejection	 episode	 by	 3	months.	 For	 the	 pa-
tients	 receiving	 high-	dose	 VGCV,	 BPAR	 occurred	 before	 the	 CMV	


































ease,	 at	 12	months	 post	 transplant	 was	 comparable	 between	 the	
groups	 (low-	dose=20.6%	 vs	 high-	dose=28.1%;	 P=.156)	 (Table	3).	
A	closer	 look	at	 the	 individual	pathogens	 revealed	 that	 the	 rates	of	
BK	virus	and	herpes	 infections	seen	within	the	groups	were	similar,	
but	 thrush	 (1.8%	vs	5.6%,	P=.049),	 systemic	 fungal	 infections	 (0.5%	
vs	3.4%,	P=.045),	and	other	OI	(8.3%	vs	18.0%,	P=.010)	were	higher	
in	the	high-	dose	group	(Table	3).	The	proportion	of	non-	diabetic	pa-
tients	with	 confirmed	NODAT	was	 similar	 (low	 dose=7.3%	 vs	 high	
dose=6.7%,	P=1.000)	at	the	end	of	the	evaluation	period	(Table	3).
4  | DISCUSSION






Odds ratio 95% CI P- value
Group	(ref=450	mg) 1.56 0.41–	5.89 .513
Nonwhite	(ref=White) 0.88 0.32– 2.39 .800
Donor	type	(ref=LD)
SCD 0.38 0.13–	1.15 .376
Other	types 0.41 0.08–	2.07 .603
rATG	induction 2.64 0.72–	9.67 .143





Hazard ratio 95% CI P- value
Group	(ref=450	mg) 1.52 0.42–	5.50 .527
Nonwhite	(ref=White) 0.86 0.33–2.28 .767
Donor	type	(ref=LD)
SCD 0.39 0.13–115 .088
Other	types 0.42 0.09–2.02 .280
rATG	induction 2.42 0.68–8.62 .173
Early	VGCV	discontinuation 5.43 1.51–19.58 .010
CI,	confidence	interval;	ref,	reference;	LD,	living	donor;	SCD,	standard	cri-
teria	donor;	rATG,	rabbit	anti-	thymocyte	globulin;	VGCV,	valganciclovir.
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in	 D+/R+	 RTR.6,7	 The	 suggested	 prophylaxis	 agents	 and	 doses	 for	









tiple	 transplant	 centers	 indicates	 that	 a	 3-	month	VGCV	prophylaxis	
at	 either	 450	mg/day	 or	 900	mg/day	 is	 effective	 in	 the	 CMV	 D+/
R+	 population.	 Despite	 the	 major	 concern	 for	 emergence	 of	 GCV-	
resistance	with	low-	dose	VGCV	prophylaxis,	we	did	not	observe	any	









VGCV	achieves	GCV	exposure	 comparable	 to	 that	of	oral	GCV	3	g/
day.	These	 analyses	 concluded	 that	 low-	dose	VGCV	provides	 ample	
drug	exposure	for	effective	CMV	prophylaxis.27–31	Kalil	et	al.32	demon-









antiviral	 prophylaxis.	 Despite	 this,	 early	 VGCV	 discontinuation	 was	

















is	 important,	 as	 drug	 cost	 is	 a	 known	 risk	 factor	 for	 medication	
non-	adherence.31–33
We	 acknowledge	 our	 study’s	 limitations.	 Data	 were	 collected	
retrospectively	 and	 the	 safety	 analysis	was	 based	 on	 singular	 time	
points	with	a	small	window	for	evaluation	(i.e.,	laboratory	values	were	











of	 the	 regimen	used	 in	 this	 study.	We	depended	on	 local	CMV	di-
agnoses,	 and	 evaluation	 of	 GCV-	resistance,	 laboratory	 data,	 and	
transplant-	related	outcomes.	A	 thorough	evaluation	of	all	 concomi-
tant	non-	immunosuppressive	medications	was	not	undertaken.	Data	

















of	 a	 prospective,	 blinded,	 randomized	 evaluation	 is	 needed	 to	 truly	
evaluate	the	exact	differences	between	these	2	dosing	regimens.
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